Butler National Golf Club
A business-educated resident of Chicago, Illinois, James “Jim” Neumann serves as president of OOS Investments, an advertising company specializing in billboards. When he isn’t assisting clients throughout the United States with high-tech billboards, James Neumann enjoys playing golf.
Each year, Golf Digest ranks the top 100 courses in the United States as well as the best in each state. Below are the best-ranked courses in Illinois for the 2017-18 season.
1. Chicago Golf Club – Located in Wheaton, this 6,846-yard, par-70 course was No. 14 on Golf Digest’s America’s 100 Greatest Course rankings. It is debated among golf historians whether it is the first ever 18-hole course in the country.
2. Butler National Golf Club – Ranked No. 45 on the publication’s America’s 100 Greatest Course rankings, Butler National Golf Club was created in 1974 by George and Tom Fazio and redesigned in 1988, 2005, and 2008.
3. Medinah Country Club – First designed by Tom Bendelow in 1928, the No. 3-ranked course at Medinah Country Club has hosted a number of major PGA tournaments since 1949. In 2012, the course hosted the Ryder Cup, for which architect Rees Jones constructed a new par-4, 15th hole. It has been listed among America’s 100 Greatest Course rankings since 1966.
Memphis Marathon Weekend
An executive in the billboards industry, James (Jim) Neumann serves as president of OOS Investments in Chicago. In this role, he owns dozens of billboards throughout the country. Also active in charitable giving, James Neumann contributes to the St. Jude Children’s Research Hospital, which will hold its annual Memphis Marathon Weekend on November 30-December 2, 2017.
The St. Jude Memphis Marathon Weekend begins with an Expo and packet pick-up at the Memphis Cook Convention Center on Friday from 12:00 to 7:00 p.m. and on Saturday from 12:00 to 9:00 p.m. The marathon will take place on Saturday and will take participants through a number of landmarks in the city of Memphis.
One of the highlights of the race lies near mile five, where participants will pass through the St. Jude campus to the cheers of patients and their families. Participants will also cross Overton Park, Overton Square, and multiple historic areas before reaching the finish line at AutoZone Park. The course will feature 24 hydration stations and a number of spirit stations to encourage racers along with Memphis music and other forms of entertainment.
Runners must be at least 16 years old and must complete the course within six hours. All runners will receive a clear gear bag, a long-sleeved tech T-shirt, a race number with a timing tag, and a finisher medal. Those interested in contributing to the cause without running a full marathon can sign up for the half marathon, 5K, or 10K.
Gene Therapy Research
A Chicago-based advertising executive specializing in billboards, James “Jim” Neumann serves as president of OOS Investments. Outside of his work, James Neumann supports the efforts of St. Jude Children’s Research Hospital.
Currently the largest pediatric medical research organization in the United States, St. Jude Children’s Research Hospital sponsors a wide variety of research in the field of gene therapy. Until recently, children with inherited genetic diseases had few treatment options, most of which focused on controlling symptoms rather than addressing the underlying cause. Gene therapy provides a way to introduce new genetic material into a patient’s cells, potentially alleviating symptoms of the disorder or reversing the disease course altogether.
In recent years, St. Jude has led gene therapy research efforts for X-linked severe combined immunodeficiency (SCID), a devastating immune disorder requiring isolation from otherwise normal situations. In 2016, researchers at St. Jude announced that patients with X-linked SCID who had undergone gene therapy demonstrated a high level of immune function two years later, with an additional three patients showing positive changes after six to nine months. Although more research must be done, researchers at St. Jude are optimistic about the potential of gene therapy to treat genetic disorders.